Sci Show: An RNA vaccine candidate for SARS-CoV-2, BNT162b1, is shown to induce a robust immune response in healthy adults aged 18–55 years in an interim report of a phase 1/2 clinical trial published in Nature.

Thursday, August 20, 2020

An RNA vaccine candidate for SARS-CoV-2, BNT162b1, is shown to induce a robust immune response in healthy adults aged 18–55 years in an interim report of a phase 1/2 clinical trial published in Nature.

https://ift.tt/31dGXsO via /r/science https://ift.tt/32adsrf

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)